158 related articles for article (PubMed ID: 31537867)
21. Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.
Vastrad B; Vastrad C; Godavarthi A; Chandrashekar R
Med Oncol; 2017 Sep; 34(11):182. PubMed ID: 28952134
[TBL] [Abstract][Full Text] [Related]
22. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
23. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
[TBL] [Abstract][Full Text] [Related]
24. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
[TBL] [Abstract][Full Text] [Related]
25. Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.
Brown CE; Warden CD; Starr R; Deng X; Badie B; Yuan YC; Forman SJ; Barish ME
PLoS One; 2013; 8(10):e77769. PubMed ID: 24204956
[TBL] [Abstract][Full Text] [Related]
26. Genetic mutations in high grade gliomas of the adult spinal cord.
Nagaishi M; Nobusawa S; Yokoo H; Sugiura Y; Tsuda K; Tanaka Y; Suzuki K; Hyodo A
Brain Tumor Pathol; 2016 Oct; 33(4):267-269. PubMed ID: 27236270
[No Abstract] [Full Text] [Related]
27. Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis.
Geng RX; Li N; Xu Y; Liu JH; Yuan FE; Sun Q; Liu BH; Chen QX
Dis Markers; 2018; 2018():3215958. PubMed ID: 30405856
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Alterations in miRNA Expression in Matched Tissue and Blood Samples during Spinal Cord Glioma Progression.
An T; Fan T; Zhang XQ; Liu YF; Huang J; Liang C; Lv BH; Wang YQ; Zhao XG; Liu JX; Fu YH; Jiang GJ
Sci Rep; 2019 Jun; 9(1):9169. PubMed ID: 31235820
[TBL] [Abstract][Full Text] [Related]
29. Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis.
Chen TY; Liu Y; Chen L; Luo J; Zhang C; Shen XF
Carcinogenesis; 2020 Jul; 41(6):743-750. PubMed ID: 31761927
[TBL] [Abstract][Full Text] [Related]
30. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
31. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
32. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
Sloan EA; Cooney T; Oberheim Bush NA; Buerki R; Taylor J; Clarke JL; Torkildson J; Kline C; Reddy A; Mueller S; Banerjee A; Butowski N; Chang S; Mummaneni PV; Chou D; Tan L; Theodosopoulos P; McDermott M; Berger M; Raffel C; Gupta N; Sun PP; Li Y; Shah V; Cha S; Braunstein S; Raleigh DR; Samuel D; Scharnhorst D; Fata C; Guo H; Moes G; Kim JYH; Koschmann C; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Phillips JJ; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Nov; 138(5):877-881. PubMed ID: 31515627
[No Abstract] [Full Text] [Related]
33. Analysis of gene expression profiles associated with glioma progression.
Hu G; Wei B; Wang L; Wang L; Kong D; Jin Y; Sun Z
Mol Med Rep; 2015 Aug; 12(2):1884-90. PubMed ID: 25845910
[TBL] [Abstract][Full Text] [Related]
34. Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury.
Nagashima Y; Nishimura Y; Ohka F; Eguchi K; Aoki K; Ito H; Nishii T; Oyama T; Hara M; Kitano Y; Masaki H; Wakabayashi T; Natsume A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685506
[TBL] [Abstract][Full Text] [Related]
35. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
36. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
37. Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV.
Narsia N; Ramagiri P; Ehrmann J; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):261-271. PubMed ID: 28452381
[TBL] [Abstract][Full Text] [Related]
38. Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study.
Liu J; Zheng M; Yang W; Lo SL; Huang J
J Neurooncol; 2018 Sep; 139(3):609-616. PubMed ID: 29796723
[TBL] [Abstract][Full Text] [Related]
39. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiles for insular low-grade gliomas with putamen involvement.
Zhou C; Wang Y; Liu X; Liang Y; Fan Z; Jiang T; Wang Y; Wang L
J Neurooncol; 2018 Jul; 138(3):659-666. PubMed ID: 29556911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]